RCKT
Rocket Pharmaceuticals, Inc.NASDAQHealthcare$3.46-2.54%ClosedMarket Cap: $375.6M
As of 2026-04-07
Valuation
P/E (TTM)
—
PEG
—
P/B
1.39
P/S
0.00
EV/EBITDA
-1.56
DCF Value
$0.47
FCF Yield
-50.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-65.8%
ROA
-67.5%
ROIC
-76.4%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | NaN% | $-44.0M | $-42.5M | $-0.38 | — |
| FY 2025 | $0.00 | -Infinity% | $-228.5M | $-223.1M | $-2.01 | — |
| Q3 2025 | $0.00 | NaN% | $-52.2M | $-50.3M | $-0.45 | — |
| Q2 2025 | $0.00 | NaN% | $-71.1M | $-68.9M | $-0.62 | — |
| Q1 2025 | $0.00 | NaN% | $-64.4M | $-61.3M | $-0.56 | — |
| Q4 2024 | $0.00 | NaN% | $-62.7M | $-60.3M | $-0.62 | — |
| FY 2024 | $0.00 | NaN% | $-273.2M | $-258.7M | $-2.73 | — |
| Q3 2024 | $0.00 | NaN% | $-69.4M | $-66.7M | $-0.71 | — |
| Q2 2024 | $0.00 | -Infinity% | $-73.7M | $-69.6M | $-0.74 | — |
| Q1 2024 | $0.00 | -Infinity% | $-67.4M | $-62.1M | $-0.66 | — |
| Q4 2023 | $0.00 | NaN% | $-63.3M | $-59.7M | $-0.64 | — |
| FY 2023 | $0.00 | NaN% | $-259.7M | $-245.6M | $-2.92 | — |